Emerging approaches to enhance human brain organoid physiology

This review addresses the core question of how to enhance the physiological relevance of human brain organoids to better model brain development, function, and disease. The authors outline the context that, while brain organoids have transformed neuroscience research, they still fall short of faithfully mimicking in vivo physiology due to limitations in quality, reproducibility, cellular diversity, maturation, tissue architecture, ECM composition, and vascularization. The purpose is to synthesize emerging strategies across the organoid workflow: optimizing pluripotent stem cell (PSC) states and culture conditions; early, nuanced morphogen administration to improve regional specification; engineering tissue architecture and fluid dynamics; tuning ECM scaffolds and endogenous niche formation; expanding cellular diversity (oRGs, astrocytes, oligodendrocytes, microglia, endothelial cells); building inter-regional assembloids; and leveraging in vivo xenotransplantation to overcome maturation bottlenecks. The importance lies in integrating these interconnected factors to increase fidelity, reproducibility, and functional maturity for both healthy development and disease modeling.

The review synthesizes a broad body of work demonstrating that organoid physiology depends on interlinked variables across stem cell fitness, morphogen patterning, architecture, ECM, cellular diversity, vascularization, and in vivo environment.

• Stem cell fitness: PSC line genetic/epigenetic variation and culture conditions influence differentiation capacity and organoid outcomes (e.g., frequent acquired mutations in PSC lines; MEF-induced TGFβ signaling establishing an intermediate pluripotent state beneficial for cortical organoids; feeder-free cultures optimized with TGFβ cocktails; FGF inhibition at PSC stage promoting neural commitment via WNT5A methylation). Controlled-release factors (FGF2/TGFβ) can improve cortical patterning and reproducibility.
• Early specification and morphogen strategies: Dual SMAD inhibition is foundational for forebrain induction, while adding Wnt inhibition (Triple-i) enhances cortical identity, oRG abundance, and neuronal diversification. Dynamic morphogen gradients (microfluidics, manual gradual media switches, morphogen-soaked beads, inducible/optogenetic SHH) increase regional fidelity and create organizing centers, generating spatially patterned organoids (e.g., dorsal-ventral ganglionic eminence, orthogonal WNT/SHH gradients).
• Tissue architecture: Single-rosette models (manual isolation, 2D-to-3D transition, micro-patterning) increase consistency. Physical cues (microfibers, chip constraints) expand the neuroepithelium and capture folding mechanics; protocol designs (pulse Wnt activation, temporal TGFβ gradients) can enforce NSC expansion and improve cortical features. Slicing and air-liquid interface (ALI) cultures reduce necrotic cores, enhance neuronal maturation and layered architecture. Fluid dynamics (orbital shaking speed, vertical mixing) alter polarization (apical-in vs apical-out), cilia signaling, and cell fate.
• ECM niche: Organoids self-produce ECM, but profiles differ from fetal tissue. Exogenous Matrigel benefits growth and polarity yet diverges markedly from brain ECM and may bias specification. Synthetic and natural hydrogels (PEG-laminin matrices) and composite scaffolds (Matrigel with soft alginate shells) modulate biomechanics and maturation. Decellularized brain/spinal ECMs recapitulate biochemical cues, improving neurogenesis, cortical layering, and axonal growth, with developmental stage specificity (neonatal vs adult ECM).
• Cellular diversity and maturation: Protocol modifications increase under-represented populations. LIF (via STAT3) and Triple-i expand oRGs and oSVZ thickness; PDGF-AA promotes earlier astrocytogenesis, with subtype diversification and functional traits, reaching advanced maturation post-transplantation; PDGF-AA, IGF1, and T3 promote oligodendrocyte lineage, with full myelination more robust in ventral spinal-like contexts with ALI. Microglia inclusion (primary or PSC-derived) enhances neurogenesis, axonogenesis, synaptic network formation but risks non-physiological activation in vitro; xenotransplantation supports in vivo-like identities.
• Vascularization and neurovascular unit: Co-culture with endothelial-like cells (ETV2-overexpressing PSCs, HUVECs) or vasculature organoids, chip-based vasculature, and in vivo grafting foster BBB-like features, neuronal differentiation, astrocyte maturation, and basement membrane formation, enabling disease modeling (e.g., cavernous malformations, β-amyloid effects on BBB).
• Assembloids and circuit formation: Fusions between multiple regional organoids assemble functional inter-region circuits, including interneuron migration and long-range axon tracts; complex multi-component assembloids span sensorimotor pathways. Organoid-to-organoid axon bridges promote oscillations and enable modeling of corpus callosum development and genetic deficits.
• In vivo maturation via xenotransplantation: Rodent hosts provide vascularization and microenvironmental cues, enabling functional integration and advanced maturation of astrocytes and microglia; transplantation age affects outcomes; platforms allow testing therapies and regenerative integration after injury. Collectively, these reports reveal that fine changes early in protocols propagate major effects on morphology, identity, and maturation, and that multi-factor integration is often required for robust in vivo resemblance.

As a review, the paper compiles methodological advances rather than presenting a single experimental protocol. Key methodological domains include:

• PSC optimization: Comparing feeder-dependent (MEFs) vs feeder-free (mTeSR1) PSC maintenance; supplementing feeder-free cultures with TGFβ mixtures to emulate intermediate pluripotent states; tailoring TGFβ inhibition to line-specific TGFBR1 expression; transient FGF inhibition at PSC stage to epigenetically predispose neural commitment; controlled-release delivery of FGF2/TGFβ to stabilize patterning.
• Morphogen administration paradigms: Using dual SMAD inhibition for neural induction and adding Wnt inhibition (Triple-i) to heighten cortical fate; combining dual SMAD with Wnt activation and FGF8b for cerebellar organoids; applying temporal gradients via microfluidics or manual stepwise media transitions; introducing spatial gradients with morphogen-soaked beads; engineering endogenous organizing centers through doxycycline-inducible or optogenetic SHH expression; leveraging multiplexed morphogen screens with single-cell RNA-seq.
• Architecture engineering: Generating single-rosette organoids by rosette isolation or converting micro-patterned 2D neuroepithelium to 3D; chip-based methods to form patterned neural tube-like structures; expanding apical surface areas with microfibers; imposing physical constraints to model folding; modulating fluid dynamics (orbital shaking speed, vertical mixing) to affect polarity and cell fate; slicing organoids and ALI culture to improve diffusion, survival, and maturation; embedding porous materials (e.g., silk fibers) to enhance patterning and reduce necrosis.
• ECM modulation: Culturing with or without exogenous ECM (Matrigel) to assess endogenous niche formation; introducing synthetic hydrogels (PEG-laminin) and composite scaffolds (Matrigel + soft alginate shells) to balance biochemical cues and mechanical confinement; employing decellularized CNS ECM (adult/neonatal brain, spinal cord) to better mimic biochemical composition and support neurogenesis, layering, and axon growth.
• Cellular complexity enhancement: Boosting oRGs with LIF (STAT3 activation) and Triple-i; early astrocyte promotion with PDGF-AA (JAK/STAT) while maintaining concurrent neurogenesis; accelerating oligodendrocyte lineage with PDGF-AA, IGF1, T3; integrating microglia (primary or PSC-derived) to modulate neurogenesis, axonogenesis, and network synchrony; incorporating endothelial/perivascular cells (ETV2 PSCs, HUVECs, pericyte-like cells) to form neurovascular units.
• Assembloids and long-range connectivity: Fusing different regional organoids to assemble circuits (ventral forebrain to cortex, midbrain-striatum-cortex, sensorimotor pathways); connecting organoids via microdevices to form axon tracts and study oscillations and genetic models.
• In vivo xenotransplantation: Transplanting organoids into rodent brains (postnatal/adult) to achieve vascularization, functional integration, and physiologically mature identities; optimizing donor organoid age; monitoring grafts with microelectrode arrays and two-photon imaging; miniaturization to improve engraftment. These methodologies are framed as tunable, often interdependent levers to increase physiological fidelity of brain organoids.

• PSC variability impacts organoid fidelity: 22% of 146 PSC lines contained at least one cancer-related mutation, 64% of these were TP53 mutations, underscoring the need to monitor genetic integrity and use multiple lines.
• PSC culture state shapes outcomes: MEF-induced diverse TGFβ signaling creates an intermediate pluripotent state optimal for cortical organoids; feeder-free cultures supplemented with TGFβ cocktails recapitulate improved architecture. Tailoring TGFβ inhibition strength to line-specific TGFBR1 expression and transient FGF inhibition (linked to WNT5A methylation and non-canonical Wnt suppression) enhance organoid formation and neural commitment.
• Early morphogen tuning yields major effects: Triple-i (dual SMAD + Wnt inhibition) strengthens cortical identity, increases oRG abundance, and diversifies neurons; dual SMAD alone can bias toward thalamic/cerebellar markers, while dual SMAD + Wnt activation + FGF8b produces cerebellar organoids. Gradual media transitions promote enhanced cortical fate and organization into a single neuroepithelium; spatial morphogen gradients via microfluidics or beads enable region-specific patterning and organizing centers.
• Architecture manipulations improve physiology: Single-rosette organoids increase reproducibility; physical supports (microfibers, chips) expand apical surfaces and model folding; slicing + ALI culture reduces necrotic cores and enhances maturation; fluid dynamics adjustments (shaking speed, vertical mixing) alter polarity and identity via cilia signaling.
• ECM composition matters: Without Matrigel, organoids show reduced growth and delayed neuroepithelial polarization, with shifts in cell-type proportions; decellularized brain/spinal ECM enhances neurogenesis, cortical layering, and axonal growth, with neonatal ECM outperforming adult in certain contexts; composite scaffolds (Matrigel + soft alginate) balance biochemical and mechanical cues to improve growth and maturation.
• Under-represented populations can be increased: LIF and Triple-i expand oRGs and oSVZ thickness via STAT3; PDGF-AA advances astrocyte emergence and maturation (diverse subtypes), with full maturation after in vivo transplantation; PDGF-AA, IGF1, T3 drive oligodendrocyte lineage, with robust myelination in ventral spinal organoids and ALI.
• Immune and vascular inclusion enhances function: Microglia integration boosts neurogenesis, axonogenesis, and network synchrony, but long-term in vitro can induce non-physiological activation; xenotransplantation restores in vivo-like identities. Endothelial/perivascular inclusion and vasculature organoids produce BBB-like features, promote neuronal differentiation and astrocyte maturation, and enable modeling of neurovascular diseases.
• Assembloids form functional circuits: Multi-regional fusions enable interneuron migration, inter-region network activity, and long-range axon tracts; organoid connections via microdevices support oscillations and modeling of callosal development and gene perturbations.
• Xenotransplantation accelerates maturation: In vivo hosts vascularize grafts and provide cues for functional integration; donor age influences engraftment stability; platforms permit testing therapies (e.g., antisense for Timothy syndrome) and regenerative repair in injury models. Overall, small, early protocol changes and integrated multi-factor strategies have outsized impacts on morphology, identity, diversity, maturation, and functional relevance of brain organoids.

The reviewed evidence demonstrates that enhancing brain organoid physiology requires a coordinated strategy across PSC conditioning, morphogen timing and gradients, physical architecture, ECM composition, cellular diversity, vascularization, and in vivo environmental cues. These factors are interconnected: for example, temporal TGFβ gradients simultaneously improved cortical specification and yielded a single expanded neuroepithelium; architecture influences diffusion, cell morphology, and identity; ECM composition can bias specification and endogenous niche formation; including microglia or endothelial cells not only adds cell types but also reshapes neuronal differentiation and astrocyte maturation through reciprocal signaling; and xenotransplantation can correct non-physiological states and promote maturation that stalls in vitro. Addressing the research question, the findings outline practical, tunable levers to make organoids more tissue-like, increasing relevance for modeling development and disease. Importantly, variability across PSC lines and protocols necessitates tailored, standardized approaches and large-scale screening to discover line-specific optimal conditions. The significance to the field is twofold: (1) improved fidelity and reproducibility unlock deeper mechanistic insights into human neurodevelopment and pathophysiology; (2) advanced maturation and multi-cellular complexity expand applications to neural circuits, neurovascular interactions, immune-neural crosstalk, and testing therapeutic interventions in more realistic contexts. The review argues for integrating multiple physiological aspects concurrently, as single-factor improvements may be constrained by other unmet needs (e.g., microglia maturation dependent on in vivo milieu). Future progress hinges on coupling protocol optimization with scalability and robust benchmarking against primary tissue to ensure interpretability and generalization.

This review consolidates emerging strategies to enhance human brain organoid physiology, highlighting that early, subtle protocol modifications and multi-factor integration can produce substantial gains in tissue architecture, cellular identity, diversity, maturation, vascularization, and functional connectivity. Key contributions include: emphasizing PSC state optimization; advocating dynamic morphogen gradients and organizing centers; engineering architecture and fluid dynamics; designing ECM environments closer to brain tissue; expanding under-represented glial and immune populations; creating vascularized organoids and BBB-like units; and leveraging assembloids and xenotransplantation to build complex circuits and achieve advanced maturation. Future directions include: systematic, tailored PSC culture protocols validated by high-throughput screens; standardized, brain-like ECM matrices informed by in vivo spatial proteomics; integrated multi-factor pipelines combining ECM, architecture, and morphogen control; scalable, reliable production methods enabling long-term maturation; deeper characterization of glial regional diversity and immune-adaptive interactions; and harmonized in vivo/in vitro platforms to translate organoid discoveries into disease modeling and therapy testing with higher fidelity, including for adult brain conditions.

• PSC heterogeneity and acquired mutations (e.g., frequent TP53 mutations) compromise reproducibility, necessitating genetic monitoring and multi-line validation.
• Protocol-specific and line-specific responses to morphogens lead to variable regional identities and outcomes, challenging standardization.
• Architectural constraints (multi-rosette growth, diffusion limits) cause necrotic cores and hinder maturation, requiring slicing or engineered scaffolds.
• ECM reliance on Matrigel introduces non-brain-like biochemical composition and batch variability; endogenous ECM production remains distinct from fetal brain; effects of ECM timing, administration method, and PSC line differences are incompletely characterized.
• Under-representation and incomplete maturation of key cell types (oRGs, astrocytes, oligodendrocytes) in vitro; robust myelination and astrocyte subtype maturation often depend on in vivo cues.
• Microglia exhibit non-physiological activation during long-term in vitro culture; inclusion of adaptive immune components is limited.
• Vascularization remains partial in vitro and BBB functionality is still being refined; chip-based approaches are early-stage.
• Assembloids can form circuits but overall neuronal maturation and in vivo-like architecture may remain incomplete.
• Xenotransplantation introduces cross-species differences and variable outcomes based on host species, brain region, and organoid age; interpretation requires caution.
• Scalability and uniform phenotypes across batches and laboratories remain challenging, impacting reproducibility and long-term studies.